Viking Therapeutics Announces Positive 52|Week Histologic Data ...

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated ...

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

SAN DIEGO, June 3, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ... As previously reported, the study successfully achieved its primary endpoint ...

Viking Therapeutics Reports Second Quarter 2024 Financial Results ...

Reported Positive 52-Week Histologic Data from Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis in 2Q24 ...

Viking Therapeutics Reports Positive 52-week Histologic Data From ...

The results announced today highlight achievement of secondary endpoints evaluating histologic changes assessed by hepatic biopsy after 52 weeks ...

Viking Therapeutics Reports Third Quarter 2024 Financial Results ...

During the second quarter, the company announced positive 52-week histology results from the Phase 2b VOYAGE trial evaluating VK2809 in ...

Viking Therapeutics Reports Positive 52-Week Data from Phase 2b ...

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, recently shared positive 52-week histologic data from its Phase 2b ...

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic ...

Viking Therapeutics (VKTX) Reports Positive 52-Week Histologic ...

Viking Therapeutics, Inc. (NASDAQ: VKTX) today announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, ...

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

Viking Therapeutics VKTX announced positive 52-week histologic data from the phase IIb VOYAGE study that evaluated VK2809 in patients with biopsy-confirmed non ...

Viking Therapeutics Announces Positive 52-Week Histologic Data ...

Viking Therapeutics, Inc. announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, the company's novel ...

Viking Therapeutics Reports Third Quarter 2024 Financial Results ...

During the second quarter, the company announced positive 52-week histology results from the Phase 2b VOYAGE trial evaluating VK2809 in patients ...

Viking Therapeutics - BioSpace

Viking Therapeutics · Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non- ...

Viking Therapeutics, Inc. (1VT.F) - Yahoo Finance

... Viking Therapeutics Announces Positive 52-Week Histologic Data ...

News & Events - Viking Therapeutics

The company expects to report the initial data from the oral formulation Phase 1 study in 1Q24. Histology Results for Phase 2b VOYAGE Study ...

News & Events - Viking Therapeutics

News & Events. Investors. << Back. Viking Therapeutics Announces Positive ... week biopsy data from this study in the first half of next year.

Viking Therapeutics Reports First Quarter 2024 Financial Results ...

We plan to report data on histologic changes assessed after 52 weeks of treatment later this quarter. Finally, during the first quarter, the ...

VKTX Viking Therapeutics Inc. - Quantisnow

$VKTX. Biotechnology: Pharmaceutical Preparations. Health Care. Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of ...

VKTX | Viking Therapeutics Announces Positive 52-Week Histologic ...

VKTX | Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non ...

Viking Therapeutics Reaps the Rewards of Positive Data

The San Diego-based Viking (Nasdaq: VKTX) announced plans to advance its injectable weight loss drug VK2735 into a Phase 3 clinical trial.

VKTX Viking Therapeutics, Inc. Latest Press Releases - Seeking Alpha

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic ...